Rituximab is a drug typically used to treat a variety of auto immune diseases as well as certain types of cancer. There is limited existing evidence in its effectiveness in treating the rare disease idiopathic membranous nephropathy (IMN).
In order to gather evidence to inform commissioning decisions NHS England is working with KiTEC to assess the effectiveness of Rituximab in treating patients with IMN. Participating insitutions will collect data on Rituximab in IMN patients, which will be recorded in an adaptation of the UK Renal Registry. Once the data is collected it will be sent to KiTEC for analysis.